Pfizer posts MET097 obesity results; registers new Phase 3 obesity and dermatitis trialsAug 28Weekly roundup, 6 itemsberobenatidePF-08154225
Nuvectis Pharma registers Phase 1b trial of NXP900 plus lorlatinib in ALK+ NSCLCAug 25Trial updatelorlatinibNuvectis Pharma, Inc.
Nuvectis reports Q2 2026 results as ciprocopan wins first China approvalAug 4Quarterly updateNuvectis Pharma, Inc.
Pfizer wins five FDA label updates for tofacitinib, ritlecitinib, abrocitinib; Crohn's trial haltedJul 2Weekly roundup, 12 itemsabrocitinibatirmociclib
Sign inSign in